Experienced Biopharmaceutical Executive Steve Glover Joins Insmed; Will Lead Development of Follow-on Biologics
25 Juin 2007 - 3:00PM
Business Wire
Insmed Inc. (Nasdaq:INSM) today announced that Steve Glover, 48,
has joined Insmed�s management team as President of the newly
formed Follow-on Biologics business, effective June 22, 2007. Mr.
Glover will be responsible for leading the development of Insmed�s
follow-on biologics capability and its emerging portfolio of
biogeneric/biosimilar products. Mr. Glover brings nearly 25 years
of business experience in bio-pharmaceuticals and life sciences to
his new position. Prior to joining Insmed, he held the position of
Senior Vice President and General Manager at Andrx Laboratories and
Andrx Therapeutics, both divisions of Andrx Corporation. He earlier
held multiple sales, marketing and operational roles at Hoffman
LaRoche, Amgen Inc. and IMS Health. His strategic and operational
experience, which covers most therapeutic classes of
biopharmaceuticals, includes strategic planning, corporate
development, operations management, product development, product
marketing and sales management. Mr. Glover commented, �I am excited
to join the talented management team that Insmed has assembled -- a
team able to leverage Insmed�s advanced knowledge of biologics
development, its manufacturing capability, and its skilled
scientific and technical workforce to make it the first U.S.-based
biotechnology company to develop a comprehensive portfolio of
follow-on biologics. This is an organization that knows the drug
industry is on the threshold of its second generic revolution.� Dr.
Geoffrey Allan, President and Chief Executive Officer of Insmed,
commented, �We are looking forward to benefiting from Steve�s
extensive leadership experience in the bio-pharmaceutical and life
sciences sectors. His expertise will be instrumental in providing
the strategic direction and tactical capability to take full
advantage of our unique combination of protein know-how and drug
approval skills. He will play a pivotal role in our follow-on
biologics strategy, which together with the development of our
approved flagship product IPLEX� in niche markets, forms a
dual-path approach for success.� About Insmed Insmed is a
bio-pharmaceutical company focused on the development and approval
of drugs for the treatment of metabolic diseases with unmet medical
needs. For more information, please visit www.insmed.com. To be
added to Insmed�s investor lists, please contact Haris Tajyar at
htajyar@irintl.com or at 818-382-9702. Forward-Looking Statements
This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Investors are cautioned that such statements in this
release, including statements relating to planned clinical study
design, regulatory and business strategies, plans and objectives of
management, and growth opportunities for existing or proposed
products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ
materially from those anticipated by the forward-looking
statements. The risks and uncertainties include, without
limitation, risks that product candidates may fail in the clinic or
may not be successfully marketed or manufactured, the Company may
lack financial resources to complete development of product
candidates, the FDA may interpret the results of studies
differently than the Company, competing products may be more
successful, demand for new pharmaceutical products may decrease,
the bio-pharmaceutical industry may experience negative market
trends, and other risks and challenges detailed in the Company�s
filings with the U.S. Securities and Exchange Commission, including
the Company�s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2007. Readers are cautioned not to place undue reliance
on any forward-looking statements which speak only as of the date
of this release. The Company undertakes no obligation to publicly
release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances that
occur after the date of this release or to reflect the occurrence
of unanticipated events.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024